Orally Administrated JBM-TC4 Prevents Acute Radiodermatitis in Breast Cancer Patients

NCT02289365 · clinicaltrials.gov ↗

PHASE2

Phase

UNKNOWN

Status

120

Enrollment

INDUSTRY

Sponsor class

Conditions

Radiodermatitis

Interventions

DRUG: 2000 mg of JBM-TC4 per day
DRUG: 3000 mg of JBM-TC4 per day
DRUG: 3000 mg of PEG-400 per day

Sponsor

Joben Bio-Medical Co., Ltd.

Collaborators

[object Object]
[object Object]
[object Object]